Brief: Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
20/11/2024 12:38
Nov 20 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE INITIATES TUSCANY PHASE 1/2 STUDY FOR NEWLY
DIAGNOSED AML
PATIENTS TO RECEIVE TUSPETINIB-BASED TRIPLET THERAPY
Source text: ID:nGNXxrDMt
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting